Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2020-04-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
独立董事关于公司第三届董事会第十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors of Zhengzhou Antu Bioengineering Co., Ltd. providing prior approval opinions on matters to be discussed at the company's 12th meeting of the third board of directors. It mentions the appointment of the 2020 audit firm and related party loan transactions. The document is short (579 characters) and serves as an opinion or approval statement rather than a full report or financial statement. It does not contain financial data or detailed audit results, nor is it a regulatory announcement or certification. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and approvals.
2020-04-28 Chinese
独立董事关于公司第三届董事会第十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various proposals discussed at the company's third board meeting, including profit distribution, auditor appointment, use of raised funds, guarantees, accounting policy changes, related party loans, and cash management. It references compliance with laws and regulations and confirms no harm to shareholders' interests. The document is not a full financial report but an opinion on board meeting matters, specifically related to governance and board decisions. It is not an announcement of voting results, nor a full annual or interim report. The content aligns with Board/Management Information (MANG) as it concerns board meeting decisions and related opinions.
2020-04-28 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 12th meeting of the 3rd Board of Directors of Zhengzhou Antu Bioengineering Co., Ltd. It includes voting results on various reports and proposals related to the 2019 fiscal year, such as the general manager's work report, board work report, independent directors' reports, financial statements, budget, profit distribution plan, audit committee report, internal control evaluation, and capital changes. The document repeatedly states that these items will be submitted to the 2019 Annual General Meeting for approval. The document is not the annual report itself but a board meeting resolution announcement related to the annual report and other governance matters. It is not a full annual report (10-K), nor a simple announcement of report publication (RPA), but a board/management information disclosure about board meeting decisions. The document length is 3448 characters, which is relatively short but contains substantive board meeting content and voting results. Therefore, the best fitting category is Board/Management Information (MANG).
2020-04-28 Chinese
招商证券关于安图生物2019年度募集资金的存放与使用情况之专项核查报告
Regulatory Filings
2020-04-28 Chinese
监事会关于会计政策变更的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the supervisory board regarding changes in accounting policies due to new accounting standards issued by the Ministry of Finance. It explains the background and compliance with regulations but does not contain financial statements or detailed financial data. The document is short (882 characters) and serves as an announcement or explanation rather than a full financial report. It does not fit categories like Annual Report (10-K) or Interim Report (IR). It is not a certification letter or a voting result announcement. The content is regulatory in nature, explaining compliance with accounting standards and approval by the supervisory board. Therefore, it best fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-04-28 Chinese
2019年度控股股东及其他关联方资金占用情况专项说明
Regulatory Filings
2020-04-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.